A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-04-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: cancerqtsyndromeqtcnervous system
  Phrases that lowered it: healthytabletblood pressurebioavailabilitythe trial
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 6.2% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 103 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: none (lowers risk) · Design
• Sponsor's past trials: 536 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 50 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated NCT03315936 · started 2017 · scored riskier than 14% of active trials completed
• Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects NCT03123185 · started 2017 · scored riskier than 14% of active trials completed
• A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 894416 in the Blood NCT03722173 · started 2018 · scored riskier than 4% of active trials completed
• A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body NCT04232839 · started 2020 · scored riskier than 4% of active trials terminated
• A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood NCT03817476 · started 2019 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.